☆ 4.8 Article

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation

NEW ENGLAND JOURNAL OF MEDICINE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)

Sai-Hong Ignatius Ou et al.

Summary: This study reported the results of a clinical trial using adagrasib to treat non-small-cell lung cancer, colorectal cancer, and other solid tumors with the KRAS(G12C) mutation. The recommended phase II dose was identified as 600 mg twice a day, and it demonstrated good tolerability and antitumor activity.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer

Joshua K. Sabari et al.

Summary: Patients with KRAS-mutant NSCLC have a high propensity to develop brain metastases. Adagrasib has shown penetration into the cerebrospinal fluid and demonstrated antitumor activity in multiple preclinical models, supporting its potential clinical activity in the brain for patients with KRASG12C-mutant NSCLC and untreated brain metastases.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Letter Medicine, General & Internal

Distribution of KRASG12C Somatic Mutations across Race, Sex, and Cancer Type

Amin H. Nassar et al.

Summary: A survey of over 32,000 cancers in the GENIE registry found differences in distribution of KRAS(G12C) mutations in various cancer types and between men and women of different races. As agents capable of targeting specific mutant alleles like sotorasib become available, tumor mutation analysis is becoming increasingly important in treatment selection.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Review Oncology

Mechanisms of Resistance to KRASG12C Inhibitors

Victoria Dunnett-Kane et al.

Summary: KRAS is a commonly mutated gene in cancer, but efforts to create direct inhibitors have largely failed until recent subtype specific inhibitors have shown promise. G12C inhibitors have entered clinical trials and shown early evidence of efficacy in patients, but there are concerns about potential drug resistance.

CANCERS (2021)

添加到收藏夹

Article Oncology

P52.03 Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreaK 100

S. Ramalingam et al.

Journal of Thoracic Oncology (2021)

添加到收藏夹

Article Oncology

Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer

Kathryn C. Arbour et al.

Summary: The study found that NSCLC patients with KRAS G12C mutations have similar clinical characteristics and treatment responses to those with KRAS non-G12C mutations, with no significant differences in response to immune checkpoint inhibitors.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)

Martin Sebastian et al.

Summary: The study analyzed treatment outcomes of 1039 patients with advanced KRAS-mutant or wildtype NSCLC in Germany and found higher proportion of patients with G12C and non-G12C mutations receiving first-line treatment combined with immune checkpoint inhibitors. It was also observed that high PD-L1 expression (TPS>50%) was associated with a significantly decreased risk of mortality.

LUNG CANCER (2021)

添加到收藏夹

Review Oncology

Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches

M. Reck et al.

Summary: KRAS is the most frequently mutated oncogene in human cancer, accounting for 85% of RAS mutations, yet there are no approved targeted therapies specifically for it. Promising direct KRAS(G12C) inhibitors such as sotorasib and adagrasib have shown clinical activity in previously treated patients, signaling a new era in the treatment of KRAS-mutated NSCLC.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease

Alexander Spira et al.

Summary: This study analyzed the characteristics and treatment outcomes of patients with advanced NSCLC harboring KRAS p.G12C mutation, revealing lower survival rates in G12C patients and indicating a need for more effective novel treatments.

LUNG CANCER (2021)

添加到收藏夹

Article Oncology

Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation

Markus Y. Wu et al.

Summary: KRAS G12C mutations in lung cancer are important oncogenic mutations that exhibit distinct primary tumor imaging features and patterns of metastasis compared to lung cancers driven by other genetic alterations. These unique imaging features may provide clues to the presence of KRAS G12C NSCLC and potentially guide management strategies in the future.

CANCERS (2021)

添加到收藏夹

Article Oncology

The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin et al.

CANCER DISCOVERY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition

Jenny Y. Xue et al.

NATURE (2020)

添加到收藏夹

Article Chemistry, Medicinal

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer

Jay B. Fell et al.

JOURNAL OF MEDICINAL CHEMISTRY (2020)

添加到收藏夹

Article Oncology

Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer

Wanyuan Cui et al.

LUNG CANCER (2020)

添加到收藏夹

Article Oncology

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation

M.L. Johnson et al.

EUROPEAN JOURNAL OF CANCER (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Targeting the untargetable KRAS in cancer therapy

Pingyu Liu et al.

ACTA PHARMACEUTICA SINICA B (2019)

添加到收藏夹

Review Medicine, Research & Experimental

Personalized therapy for lung cancer: Striking a moving target

Suchita Pakkala et al.

JCI INSIGHT (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

Piro Lito et al.

SCIENCE (2016)

添加到收藏夹

Article Medicine, General & Internal

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Edward B. Garon et al.

LANCET (2014)

添加到收藏夹

Editorial Material Medicine, General & Internal

被撤回的出版物: World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects (Retracted article. See vol. 135, pg. 2149, 2021)

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)

添加到收藏夹

Article Multidisciplinary Sciences

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Jonathan M. Ostrem et al.

NATURE (2013)

添加到收藏夹

Article Oncology

Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases

MP Mehta et al.

JOURNAL OF CLINICAL ONCOLOGY (2003)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.